Chemotherapy Induced Anemia Market Size Insights Forecasts to 2030
- The Global Chemotherapy Induced Anemia Market Size was valued at USD 2.16 Billion in 2021
- The Worldwide Market is Growing at a CAGR of 7.2% from 2022 to 2030
- The Worldwide Chemotherapy Induced Anemia Market Size is expected to reach USD 3.99 Billion by 2030
- Asia Pacific expected to grow the fastest during the forecast period
Get more details on this report -
The Global Chemotherapy Induced Anemia Market Size is expected to reach USD 3.99 billion by 2030, at a CAGR of 7.2% during the forecast period 2021 to 2030.
Anemia is a common complication of myelosuppressive chemotherapy, and the development of chemotherapy-induced anemia is more common in patients with hematologic malignant tumours. Anemia is caused due to a decrease in the count of the total number of red blood cells or haemoglobin in the blood. Haemoglobin is a vital part of the red blood cells and obligates oxygen. In case the body will not receive the appropriate amount of oxygen, it means there is a less or abnormal supply of red blood cells. Chemotherapy is responsible for chemotherapy-induced anemia, which also contributes to both fatigue and bearable negatively. However, not all clinicians consistently survey, measure, or even document anemia-related symptoms. Chemotherapy-induced anemia is caused by bone marrow infiltration with disruption of erythropoiesis, malignant invasion of normal tissues leading to blood loss, and iron deficiency as a result of inflammation. The rising prevalence of cancer, expanding requirement for biopharmaceuticals, and rising preference for homecare settings are all primary reasons driving the global market of chemotherapy-induced anemia.
This research report categorizes the market for global chemotherapy induced anemia market analysis based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global chemotherapy induced anemia market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global chemotherapy induced anemia market.
Global Chemotherapy Induced Anemia Market Report Coverage
|Market Size in 2021:||USD 2.16 Billion|
|Forecast Period 2021-2030 CAGR:||7.2%|
|2030 Value Projection:||USD 3.99 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||190|
|Tables, Charts & Figures:||130|
|Segments covered:||By Anemia, By Drug Type, By End Users, By Region, and COVID-19 Impact Analysis|
|Companies Covered:||Amgen Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., FibroGen, Inc.,, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Phyto Health Corporation, SBI Pharmaceuticals, Therapure Biopharma Inc., Elseviar Inc., Panacea Biotec Ltd, Vifor Pharma AG, Zydus Cadila|
|Pitfalls & Challenges:||Covid-19 Impact Analysis|
Get more details on this report -
The major factor expected to boost the industry during the forecast period of the chemotherapy-induced anemia market is cancer among the aging population and an increase in the appearance of anemia. The population rises in chronic conditions and increasing the number of pipeline products are expected to help the industry grow. Other consequential drivers expected to drive market expansion throughout the forecast period are advancement and innovation, technical advancements, government incentives, and improvements in pipeline items. In the upcoming year, reimbursement policies are expected to bring out profitable opportunities for the expansion of the market.
In chemotherapy induced anemia, various side effects can develop the anemia and rise in several causes of anemia in cancer patients which can restrain the growth of the market. Moreover, there are several side effects and risk-related treatments also affect the growth of the market.
In 2021, the the life threatening anemia segment is dominating the market with the largest market share over the forecast period.
Based on anemia, the global chemotherapy-induced anemia market is segmented into mild anemia, moderate anemia, severe anemia, and life-threatening anemia. Among these, the life threatening anemia segment is dominating the market with the largest market share over the forecast period. life-threatening anemia occurs when your body doesn't produce enough red blood cells with hemoglobin less than 6.5 g/dL can cause death also. This Anemia mostly occurs in Asian countries like India and China, where the disease is becoming more prevalent among women.
In 2021, the hospital is dominating the market with the largest market share over the forecast period.
Based on end user, the global chemotherapy-induced anemia market is segmented into hospitals, ambulatory surgical centres multispecialty clinics, and cancer research centres. Among these, the hospital segment is dominating the market with the largest market share of 60% over the forecast period due to availability of advanced healthcare facilities and highly skilled staff at the most leading hospitals all over the world. The rising chronicity of chronic diseases such as cancer and anemia due to low hemoglobin levels is predicted to elevate the demand for chemotherapy-induced anemia treatment.
Regional Segment Analysis of the Global Chemotherapy-Induced Anemia Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share during the forecast period
Get more details on this report -
The North American region dominated the market and generated 37.22% of the global market share. North America is attributed to several factors such as favourable reimbursement policies, the increasing prevalence of cancer, and the presence of well-established healthcare facilities for market growth. The high adoption rate of novel treatment options is also expected to drive market extension. In addition, during the forecast period, the rapid adoption of new treatment options also drives regional growth for future market growth. Due to the increasing availability of several chemotherapy agents and advanced healthcare infrastructure, North America is the leading region in the global chemotherapy-induced anemia market.
The Europe region is also expected to drive market growth due to the presence of several large pharmaceutical companies operating in this region. Due to the increasing occurrence of cancer and anemia, the geriatric population is expected to display lucrative growth during the forecast period.
The report offers the appropriate analysis of the key organizations/companies involved within the chemotherapy induced anemia market analysis along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Amgen Inc.
- Astellas Pharma Inc.
- Dr. Reddy’s Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- FibroGen Inc.,
- Johnson & Johnson Services, Inc.
- Novartis AG
- Pfizer Inc.
- Phyto Health Corporation
- SBI Pharmaceuticals
- Therapure Biopharma Inc.
- Elseviar Inc.
- Panacea Biotec Ltd
- Vifor Pharma AG
- Zydus Cadila
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In July 2020, Zydus Cadila, a drug firm received approval from the US health regulator to initiate clinical trials for its drug ‘Desidustat’ in the treatment of chemotherapy-induced anemia.
- In September 2019, FibroGen, Inc. declared its first patient dosed by the company’s Phase 2 clinical study of ‘roxadustat’, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, treatment for the chemotherapy-induced anemia receiving patients.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global chemotherapy induced anemia market based on the below-mentioned segments:
Global Chemotherapy Induced Anemia Market, By Anemia
- Mild Anemia
- Moderate Anemia
- Severe Anemia
- Life-Threatening Anemia
Global Chemotherapy Induced Anemia Market, By End Users
- Ambulatory Surgical Centres
- Multispecialty Clinics
- Cancer Research Centres
- Cancer Rehabilitation Centres
Global Chemotherapy Induced Anemia Market, By Drug Type
- Androxy Oral
- Epoetin Alfa Injection
- Epogen Injection
- Procrit Injection
- Aranesp injection
Global Chemotherapy Induced Anemia Market, By Regional Analysis
- North America
- U. K.
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
Need help to buy this report?